Skip to main content
OpenTrials
Completed

NCT Number: NCT05995665

Assistive Soft Robotic Glove (EsoGLOVE) Intervention for Stroke Patients

This proposed research aims to assess the efficacy and feasibility of the EsoGLOVE in the inpatient rehabilitation setting. 1. Understanding the ability of the EsoGLOVE in providing exercise and assisting stroke patients with completing hand functional tasks, eventually improves patients' motor function and neural recovery.2. To generate evidence on this innovative device and further deploy it in clinical practice. A Health Technology Assessment (HTA) will be generated from this study to evaluate the cost-effectiveness of the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alexandra Hospital, Singapore

Loading trial locations.

About this study

This project proposes a study of 130 subjects in inpatient settings who have sustained their first-ever stroke prior to clinical trial enrolment. Participants are randomly assigned to 2 groups (EsoGLOVE group and GRASP group). The randomization method: A block randomization with a randomly varying block size. The study will last 12 weeks (3 weeks of intervention during hospitalization + 12th-week outpatient follow-up post-discharge). The subjects will use the study device about 15 times and be followed up for 3 weeks during hospitalization.

The subjects will need to visit the doctor's office 1 time (outpatient follow-up post-discharge) in the course of the study.During the hospitalization, the stroke patients (subjects) will receive intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation. On top of the standard care (daily Inpatient OT Rehabilitation), the EsoGLOVE subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day. While the GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.In the case of early discharge or withdrawal for any reason before the 3-week intervention is completed, the subjects will no longer participate in this study and no study-related activities will be performed on the subjects. The subjects' right to receive standard care will remain the same as per hospital guidelines and will not be affected. This is applicable to both groups. With minimal compliance rate (10 sessions) for continuing the study, regardless of the subjects' discharge before 3 weeks, otherwise (less than or equal to 9 sessions) subjects will be withdrawn at the day of discharge or withdrawal. The 12th-week outpatient follow-up post-discharge at the clinic will coincide with the subject's standard care follow-up visit.The Health Technology Assessment (HTA) is conducted by the study team using explicit analytical frameworks, clinical outcomes, epidemiological data amp; statistics, health economic information, and study methodology. The assessment includes building evidence on the qualities and costs of health interventions (cost-effectiveness), identifying the direct amp; indirect medical costs in the current healthcare system, capturing the clinical outcomes of interventions, synthesizing health research findings of the effectiveness of different health interventions, evaluating the economic implications and analyzing the cost-effectiveness of the intervention.It is unlikely this study might unintentionally come to know of new information (Incidental Finding) about the health condition from the assessment (Fugl-Meyer Assessment - Upper Extremity) of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 21-90 years regardless of lesion size, race
  • Stroke type: ischemic or haemorrhagic
  • Medically stable conditions
  • Fugl-Meyer Assessment (FMA) of upper extremity impairment from 8-47 out of 66, or FMA of upper extremity impairment from 48-56 out of 66 if hand and wrist subscale is not full score and may still potentially benefit from study programme.
  • Able to give own consent, comprehend and follow commands
  • Able to sit upright and maintain sitting balance for at least 45 minutes
  • Able to stay alert and focus on the tasks at least 45 minutes and more.
  • Unilateral upper limb impairment

Exclusion criteria

  • Recurrent stroke
  • Unstable medical conditions (e.g. heart attack, unstable blood pressure, infection, and etc.) or anticipated life expectancy of <1 year.
  • Significant cognitive and communicative impairment (e.g. severe receptive aphasia, inattention, learning difficulty, and etc).
  • History of severe depression or active psychiatric disorder.
  • Severe spasticity (Modified Ashworth scale >3) of the affected distal muscles, joint contractures or deformity, poor skin conditions (e.g. irritated skin, open wounds), amputation of fingers, and allergic condition (e.g. patients with allergies to adhesive gel).
  • Poor trunk control or postural hypotension.

Treatment and study plan

EsoGLOVE

Device

The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVE training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day, up to 15 sessions. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).

Graded Repetitive Arm Supplementary Program (GRASP)

Other

Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.

Primary outcomes

  1. Fugl-Meyer Assessment for the Upper Extremity

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

    upper limb impairment scale ranged from 0-66 with higher score indicating better outcome

Secondary outcomes

  1. Stroke Impact Scale-16

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

    consists of 16 items from the 4 physical domains (strength, hand function, mobility, and ADL/IADL) ranged from 16 to 80 with higher score indicating better outcome

  2. Stroke Upper Limb Capacity Scale

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

    Activities limitation of upper limb ranged 0 to10 with higher score indicating better outcome

  3. Duruoz Hand Index

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

    self-reported upper limb function ranged 0 to 90 with higher score indicating worse outcome

Sponsors and collaborators

Lead sponsor

Alexandra Hospital

Other

Collaborators

  • Jurong Community Hospital, Singapore
  • Roceso Technologies

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 16, 2023
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.